Lipoprotein alterations in patients with HIV infection: Relation with cellular and humoral immune markers

Clinica Chimica Acta

Volumn 274, Issue 1, 1998, Pages 63-70

  Fernández Miranda, Consuelo ^a   Pulido, Federico ^a   Carrillo, Juan L ^a   Larumbe, Sagrario ^a   Izquierdo, Teresa Gómez ^a   Ortuño, Blanca ^a   Rubio, Rafael ^a   Del Palacio, Angel ^a  

^a HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

Author keywords

CD4+ lymphocytes; HIV; Interferon ; Lipoproteins; Tumor necrosis factor ; 2 microglobulin

Indexed keywords

ALPHA INTERFERON; BETA 2 MICROGLOBULIN; CD4 ANTIGEN; DIDANOSINE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; RITONAVIR; SAQUINAVIR; TRIACYLGLYCEROL; TUMOR NECROSIS FACTOR ALPHA; VERY LOW DENSITY LIPOPROTEIN CHOLESTEROL; ZALCITABINE; ZIDOVUDINE;

AGED; ARTICLE; CELLULAR IMMUNITY; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMORAL IMMUNITY; LIPOPROTEIN BLOOD LEVEL; LYMPHOCYTE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL;

EID: 0032496628     PISSN: 00098981     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0009-8981(98)00050-3     Document Type: Article

References (20)

1. [1] Grunfeld C, Pang M, Doerrler W, Shigenaga JK, Jensen P, Feingold KR. Lipids, lipoproteins, triglyceride clearance, and cytokines in human immunodeficiency virus infection and the acquired immunodeficiency syndrome. J Clin Endocrinol Metab 1992;74:1045-52.
2. [2] Shor-Posner G, Basit A, Lu Y, Cabrejos C, Chang J, Fletcher M, Mantero-Atienza E. Hypocholesterolemia is associated with immune dysfunction in early human immunodeficiency virus-1 infection. Am J Med 1993;94:515-9.
3. [3] Constans J, Pellegrin JL, Peuchant E et al. Plasma lipids in HIV-infected patients: a prospective study in 95 patients. Eur J Clin Invest 1994;24:416-20.
4. [4] Grunfeld C, Kotler DP, Hamadeh R, Tierney A, Wang J, Pierson RN. Hypertriglyceridemia in the acquired immunodeficiency syndrome. Am J Med 1989;86:27-31.
5. [5] Grunfeld C, Kotler DP, Shigenaga JK et al. Circulating Interferon-I levels and hypertriglyceridemia in the acquired immunodeficiency syndrome. Am J Med 1991;90:154-62.
6. [6] Mildvan D, Machado SG, Wilets I, Grossberg SE. Endogenous interferon and triglyceride concentrations to assess response to zidovudine in AIDS and advanced AIDS-related complex. Lancet 1992;339:453-6.
7. [7] Muga R, Tor J, Rey-Joly C, Pardo A, Llobet P, Foz M. Dislipemia e infectión por VIH-1 en adictos a drogas intravenosas. Med Clin (Barc) 1993;100:161-3.
8. [8] Pulido F, Castilla V, Rubio R, Costa JR. Valor de la trigliceridemia como predictor de progresión de la infección por VIH en adictos a drogas intravenosas. Med Clin (Barc) 1993;101:277.
9. [9] Zangerle R, Sarcletti M, Gallati H, Reibnegger G, Wachter H, Fuchs D. Decreased plasma concentrations of HDL cholesterol in HIV-infected individuals are associated with immune activation. J Acquir Immune Defic Syndr 1994;7:1149-56.
10. [10] Sammalkorpi K, Valtonen V, Kerttula Y, Nikkila E, Taskinen MR. Changes in serum lipoprotein pattern induced by acute infections. Metabolism 1988;37:859-65.
11. [11] Alvarez C, Ramos A. Lipids, lipoproteins and apoproteins in serum during infection. Clin Chem 1986;32:142-5.
12. [12] Grunfeld C, Feingold KR. Tumor necrosis factor, interleukin, and interferon induced changes in lipid metabolism as part of host defense. Proc Soc Exp Biol Med 1992;200:224-7.
13. [13] Fontanals-Ferrer N, Serrat-Serrat J, Sorribas-Vivas A, González-García C, González-Sastre F, Gómez-Gerique J. Quick method of determining lipoproteins, including those of intermediate density, in serum. Clin Chem 1988;34:1753-7.
14. [14] Dezube BJ, Pardee AB, Chapman B et al. Pentoxifylline decreases tumor necrosis factor expression and serum triglycerides in people with AIDS. J Acquir Immune Defic Syndr 1993;6:787-94.
15. [15] Llobet P, Muga R, González JA, Abad E, Tor J, Rey-Joly C. El factor de necrosis tumoral alfa en la infección por el virus de la inmunodeficiencia humana. Med Clin (Barc) 1995;104:369-72.
16. [16] Krown SE, Niedzwiecki D, Bhalla RB, Flomenberg N, Bundow D, Chapman D. Relationship and prognostic value of endogenous interferon-I, β2-microglobulin, and neopterin serum levels in patients with Kaposi sarcoma and AIDS. J Acquir Immune Defic Syndr 1991;4:871-80.
17. [17] Semb H, Peterson J, Tavernier J, Olivecrona T. Multiple effects of tumor necrosis factor on lipoprotein lipase in vivo. J Biol Chem 1987;262:8390-4.
18. [18] Sherman ML, Spriggs DR, Arthur KA, Imamura K, Frey-III E, Kufe DW. Recombinant human tumor necrosis factor administered as a five-day continuous infusion in cancer patients: phase I toxicity and effects on lipid metabolism. J Clin Oncol 1988;6:344-50.
19. [19] Edgington TS, Curtiss LK. Plasma lipoproteins with bioregulatory properties including the capacity to regulate lymphocyte function and the immune response. Cancer Res 1981;41:3786-8.
20. [20] Owens RJ, Anantharamaiah GM, Kahion JB, Srinivas RV, Compans RW, Segrest JP. Apolipoprotein A1 and its amphipathic helix peptide analogues inhibit human immunodeficiency virus-induced syncytium formation. J Clin Invest 1990;86:1142-50.